Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::

李懿宬 (I-Cheng Lee)

李懿宬(I-Cheng Lee)圖 複診掛號 初診掛號

[簡介]

  • 學歷
    • 國立陽明交通大學 臨床醫學研究所 博士
    • 國立陽明交通大學 醫學系 學士
    • 美國南加州大學 分子微生物暨免疫學研究所 訪問學者
  • 經歷
    現職：
    • - 迄今 臺北榮民總醫院 內科部胃腸肝膽科 主治醫師
    • - 迄今 國立陽明交通大學 醫學系 教授
    • - 迄今 台灣肝癌醫學會 秘書長
    • - 迄今 台灣腫瘤消融醫學會 理事
    經歷：
    • - 國立陽明交通大學附設醫院 內科部 主治醫師
    • - 臺北榮民總醫院 內科部 總醫師
    • - 臺北榮民總醫院 胃腸科 總醫師
    • - 臺北榮民總醫院 內科部 住院醫師
  • 醫療專長
    1. B、C型肝炎、脂肪肝、肝硬化及其合併症治療
    2. 肝癌治療策略
    3. 肝癌熱射頻(RFA)及微波(MWA)消融術
    4. 肝癌標靶、免疫治療
    5. 內視鏡膽胰管攝影與治療(ERCP)
    6. 膽管鏡診斷與困難膽管結石碎石術
    7. 腹部超音波、胃鏡、大腸鏡診斷及治療
  • 證照
    內科專科醫師 消化系內科專科醫師 消化系內視鏡專科醫師 肝腫瘤射頻消融專業醫師證書 台灣肝癌專科醫師證書
  • 語言專長
    國語 英語

[著作]

  1. Tan CP, Lee TY, Lee IC*, Wu KC, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Chi CT, Luo JC, Hou MC, Huang YH. Patterns and Prognostic Stratification of Recurrence After Thermal Ablation in Patients with Hepatocellular Carcinoma. Liver Cancer. 2025 Dec 18. doi: 10.1159/000550105. (*Corresponding author)
  2. Lee IC, Wang HW, Teng W, Lin TJ, Chen CH, Lai HC, Lee TY, Chang CW, Hung CH, Dai CY, Hung YP, Shen YC, Su CW, Ho MC, Lee WC, Chau GY, Ting CT, Liang PC, Liu CA, Chang PY, Chen KY, Lin SM, Chen LT, Huang YH. TLCA Intermediate Stage HCC Working Group. Taiwan Liver Cancer Association Management Consensus Guidelines for Intermediate Stage Hepatocellular Carcinoma. Clin Mol Hepatol. 2025 Oct;31(4):1213-1232.
  3. Hui RW…, Chiu KW…, Lee IC…, Wang C, Cheng HM, Lu J, Mao X, Yu S, Lam LK, Mak LY, Cheung TT, Chia NH, Cheung CC, Kan WK, Wong TC, Chan AC, Huang YH, Yuen MF, Yu PL*, Seto WK*. Multimodal multiphasic pre-operative image-based deep-learning predicts hepatocellular carcinoma outcomes after curative surgery. Hepatology. 2025 Aug 1;82(2):344-356. (…Co-first author)
  4. Wu KC, Lee IC*, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Chi CT, Luo JC, Hou MC, Huang YH. Diabetes Mellitus Negatively Impacts Outcomes of HBV-Related Hepatocellular Carcinoma Following Thermal Ablation. J Hepatocell Carcinoma. 2024 Nov 19:11:2257-2267. (*Corresponding author)
  5. Lee IC*, Lei HJ, Wang LC, Yeh YC, Chau GY, Hsia CY, Chou SC, Luo JC, Hou MC, Huang YH. M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma. Liver Cancer. 2025;14(1):68-79. (*Corresponding author)
  6. Wu KC, Lee IC*, Chi CT, Liu CA, Chiu NC, Hsu SJ, Lee PC, Wu CJ, Luo JC, Hou MC, Huang YH. Impact of HCV Eradication on Recurrence Pattern and Long-term Outcomes in Patients with HCV-Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Aliment Pharmacol Ther. 2024 Oct;60(7):940-952. (*Corresponding author)
  7. Lee IC, Tsai YP, Lin YC, Chen TC, Yen CH, Chiu NC, Hwang HE, Liu CA, Huang JG, Lee RC, Chao Y, Ho SY*, Huang YH*. A Hierarchical Fusion Strategy of Deep Learning Networks for Detection and Segmentation of Hepatocellular Carcinoma from Computed Tomography Images. Cancer Imaging. 2024 Mar 26;24(1):43.
  8. Lee IC*, Lee PC, Chao Y, Chi CT, Wu CJ, Hung YP, Su CW, Hou MC, Huang YH*. Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib. Viruses 2022 Oct 26;14(11): 2355. (*Corresponding author)
  9. Lee IC*, Lan KH, Su CW, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. Efficacy and Renal Safety of Prophylactic Tenofovir Alafenamide for HBV-Infected Cancer Patients Undergoing Chemotherapy. Int J Mol Sci. 2022 Sep 26;23(19):11335. (*Corresponding author)
  10. Lee IC, Chao Y, Lee PC, Chen SC, Chi CT, Wu CJ, Wu KC, Hou MC, Huang YH*. Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2022;14(8):2014.
  11. Lee IC, Huang JY, Chen TC, Yen CH, Chiu NC, Hwang HE, Huang JG, Liu CA, Chau GY, Lee RC, Hung YP, Chao Y, Ho SY*, Huang YH*. Evolutionary Learning Derived Clinical-Radiomic Models for Predicting Early Recurrence of Hepatocellular Carcinoma After Resection. Liver Cancer. 2021;10(6):572-582.
  12. Wu KC, Lee IC*, Chi CT, Lei HJ, Chau GY, Yeh YC, Su CW, Hou TI, Chao Y, Lin HC, Hou MC, Huang YH*. Comparable Benefits of HCV Eradication by Direct Acting Antivirals and Interferon-based Therapy in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Am J Cancer Res. 2021;11(11):5526-5542. eCollection 2021. (*Corresponding author)
  13. Hung YW, Lee IC*, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH*. Redefining Tumor Burden in Patients with Intermediate Stage Hepatocellular Carcinoma: the Seven-Eleven Criteria. Liver Cancer. 2021;10(6):629-640. (*Corresponding author)
  14. Lee IC, Lei HJ, Chau GY, Yeh YC, Wu CJ, Su CW, Hou TI, Chao Y, Lin HC, Hou MC, Huang YH*. Predictors of Long-term Recurrence and Survival After Resection of HBV-related Hepatocellular Carcinoma: The Role of HBsAg. Am J Cancer Res. 2021;11(7):3711-3725.
  15. Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH*. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc. 2021;120(9):1676-1685.
  16. Lee IC, Huo TI*, Huang YH*. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020;83(6):521-523.
  17. Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH*. A New ALBI-based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma. Liver Int. 2019;39(9):1704-1712.
  18. Lee IC, Chao Y, Li CP, Su CW, Lan KH, Lin HC, Hou MC, Huang YH*. Risk of Renal Events During Tenofovir Disoproxil Fumarate and Entecavir Antiviral Prophylaxis in HBsAg-Positive Cancer Patients Undergoing Chemotherapy. J Viral Hepat. 2018;25(12):1599-1607.
  19. Lee IC, Yang SS, Lee CJ, Su CW, Wang YJ, Lan KH, Lin HC, Hou MC, Peng 10. 10. CY*, Huang YH*. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. J Infect Dis. 2018;218(7):1075-1084.
  20. Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH*. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One. 2017;12(11):e0188552.
  21. Lee IC, Sun CK, Su CW, Wang YJ, Chang HC, Huang HC, Lee KC, Huang YS, Perng CL, Liu YH, Chua CS, Lin YM, Lin HC, Huang YH*. Durability of Nucleos(t)ide Analogues Treatment in Patients with Chronic Hepatitis B. Medicine (Baltimore). 2015;94(32):e1341.
  22. Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH*. Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice. Medicine (Baltimore). 2015;94(14):e688.
  23. Lee IC, Huang YH*, Su CW, Wang YJ, Huo TI, Lee KC, Lin HC. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. PLoS One. 2013;8(10):e76798.
  24. Lee IC, Huang YH*, Chau GY, Huo TI, Su CW, Wu JC, Lin HC. Serum Interferon Gamma Level Predicts Recurrence in Hepatocellular Carcinoma Patients After Curative Treatments. Int J Cancer. 2013;133(12):2895-902.
  25. Lee IC, Lin CH, Huang YH*, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW, Lin HC, Lee SD. IL28B Polymorphism Correlates with Active Hepatitis in Patients with HBeAg-Negative Chronic Hepatitis B. PLoS One. 2013;8(2):e58071.
  26. Lee IC, Huo TI, Huang YH*, Chao Y, Li CP, Lee PC, Chiang JH, Su CW, Lan KH, Yang CM, Wu JC, Lin HC, Lee SD. Trans-arterial Chemo-embolization Can Prolong Survival for Patients with Metastatic Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Hepatol Int. 2012;6(4):753-762.
  27. Lee IC, Huang YH*, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Wu JC, Lin HC, Lee SD. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clin Nutr. 2011;30(5):647-52.
  28. Lee IC, Chan CC, Huang YH*, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Comparative Analysis of Non-invasive Models to Predict Early Liver Fibrosis in Hepatitis B e Antigen-negative Chronic Hepatitis B. J Clin Gastroenterol. 2011;45(3):278-85.
  29. Lee IC, Huang YH*, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Correlation between Clinical Indication for Treatment and Liver Histology in HBeAg-negative Chronic Hepatitis B: A Novel Role of Alpha-fetoprotein. Liver Int. 2010;30(8):1161-8.
  30. Lee IC, Huang YH*, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B Virus Reactivation After 23-months of Rituximab based Chemotherapy in an HBsAg-negative, anti-HBs-positive Patient with Follicular Lymphoma. J Chin Med Assoc. 2010;73(3):156-60.
回到最上